Quantcast

Verona Pharma closer to third phase testing nebulized ensifentrine in certain COPD treatment

Verona Pharma has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”).

Read more

Verona Pharma finds more symptoms benefits from ensifentrine in COPD patients

Verona Pharma posted Monday expanded analysis to positive results from March, from from findings from its chronic obstructive pulmonary disease (“COPD”) clinical trial program with lead product candidate, ensifentrine (RPL554). Positive results from the 4-week, 400-patient Phase 2b study were initially reported in March 2018.

Read more